Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Home
/
update
/
details

Renovaro to Acquire Predictive Oncology in All-Stock Deal

NextEdge Admin

07 Jan 2025

2 min 36 sec

Renovaro,precision medicine,biotechnology

Renovaro Inc., a leader in AI-driven cancer diagnostics and therapeutics, has signed a binding LOI to acquire Predictive Oncology in an all-stock transaction. This acquisition will enhance Renovaro’s ability to provide early cancer detection, treatment planning, and recurrence monitoring through Predictive Oncology’s AI-powered tumor-drug response prediction platform, which boasts a 92% accuracy rate.

Predictive Oncology’s proprietary AI/ML platform and biobank of over 150,000 tumor samples, 200,000 pathology slides, and decades of drug response data will significantly strengthen Renovaro’s clinical decision support capabilities. The acquisition will enable the launch of an AI-driven decision support platform for oncologists in 2025. Additionally, integrating Predictive Oncology’s small molecule drug response modeling with Renovaro’s liquid biopsy technology will accelerate biomarker discovery and clinical trial optimization.

The combined entity will operate a state-of-the-art CLIA, NYSDOH, and CA-certified lab, expediting the development and validation of diagnostic tests in Europe and expanding its global reach. A novel in vivo chemosensitivity and resistance assay will also be introduced to European markets.

The merger will establish a full-stack clinical service, combining AI-powered liquid biopsy, cancer vaccine programs, and small molecule drug discovery to create an end-to-end oncology solution. By integrating multi-omic data for drug discovery, Renovaro aims to transform cancer diagnostics and therapy, improving patient outcomes and reducing costs.

Predictive Oncology had previously announced a strategic review to maximize shareholder value, culminating in this acquisition. Renovaro will acquire 100% of its common shares through preferred stock issuance.

Renovaro is focused on advancing precision medicine by harnessing AI and biotechnology to drive early diagnosis, targeted treatments, and innovative drug discovery.